Nebulized Furosemide for Pulmonary Inflammation in Intubated Patients With COVID-19: A Phase 2 Randomized Controlled...

Area of Science:

• Pulmonology
• Critical Care Medicine
• Pharmacology

Background:

• COVID-19 respiratory failure presents significant morbidity and mortality.
• Systemic anti-inflammatory therapies for COVID-19 have limitations, including side effects.
• Inhaled furosemide offers a potential alternative due to its anti-inflammatory properties and localized delivery.

Purpose of the Study:

• To investigate the efficacy of nebulized furosemide as an adjunctive therapy for COVID-19-induced respiratory failure.
• To assess the impact of inhaled furosemide on oxygenation and clinical outcomes in mechanically ventilated patients.

Main Methods:

• A multicenter, double-blind, randomized, placebo-controlled trial was conducted.
• Adult patients requiring invasive mechanical ventilation for COVID-19 were enrolled.
• Patients received either inhaled furosemide or placebo until day 28, death, or liberation from mechanical ventilation.

Main Results:

• The trial was terminated early due to declining COVID-19 incidence, with 39 patients analyzed.
• No significant differences were observed in the primary outcome (change in PaO2/FiO2 ratio) between groups.
• Secondary outcomes, including 60-day mortality and ventilator-free days, did not show statistically significant differences, though a post hoc analysis favored furosemide for ventilator-free survival.

Conclusions:

• Inhaled furosemide did not demonstrate significant efficacy in improving oxygenation or other clinical outcomes in this underpowered trial.
• The favorable safety profile of inhaled furosemide suggests potential for further research.
• Additional studies are warranted to explore its role in conditions characterized by acute pulmonary inflammation.